Geron Corporation Securities Class Action
Analysis based on 10 articles · First reported Mar 14, 2025 · Last updated Apr 13, 2025
The market is impacted by the significant decline in Geron Corporation's stock price following the disclosure of Rytelo's flattened growth and the subsequent class action lawsuit. This event highlights the risks associated with pharmaceutical product performance and corporate transparency, potentially leading investors to scrutinize similar companies more closely.
Faruqi & Faruqi, a national securities law firm, is investigating Geron Corporation and has filed a federal securities class action lawsuit against the company. The lawsuit alleges that Geron Corporation and its executives made false and misleading statements regarding the commercial potential and risks of their drug Rytelo. Specifically, the complaint claims that Geron Corporation minimized the risks associated with Rytelo's weekly monitoring requirement, seasonality, and existing competition. On February 26, 2025, Geron Corporation announced its Q4 2024 financial results, revealing that Rytelo's growth had flattened. This news caused Geron Corporation's stock price to drop dramatically by over 32% in a single day. Faruqi & Faruqi is encouraging investors who suffered losses exceeding $100,000 between February 28, 2024, and February 25, 2025, to contact them to discuss their legal rights and the May 12, 2025, deadline to seek the role of lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard